TRXC does own ALF-X. That system is not Surgibot. It has real and up-to-date robotics technology and has been used in hundreds of clinical cases. It has value but its form factor will need to be changed to make it smaller. TRXC may find buyers for it who want a jump into the surgical robotics arena.
I think the biggest difficulty with Surgibot was that it was misrepresented to the investment public as robotic, and unsophisticated (medically and technically) investors bought into that. A more streamlined and honestly-represented version of it could have allowed it a place in providing enhancements to manual endoscopic surgery in select surgical situations.
TITXF management should be getting a lesson in that law firms will start sniffing around the surgical robotics sector with new interest in uncovering any potential lawsuits. I think this will actually stifle (as if that is needed) PR from Titan, although it might improve their transparency when it comes to IR.
News 
Market Data 
Discover 
AI
